Clear Street Assigns Buy Rating to Cullinan Therapeutics with Price Target of $33
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy CGEM?
Clear Street says that Gilead's (GILD) up to $2.2B acquisition of Ouro Medicines' sole asset OM336 underscores the potential of Cullinan Therapeutics' (CGEM) velinotamig. This M&A serves as external validation of BCMA as a target for autoimmune diseases and its ability to show benefit across multiple indications, the firm says. Notably, these indications differ meaningfully from those pursued with CD19 x CD3 bispecifics. This strategic separation in development paths curbs cannibalization risk for Cullinan Therapeutics' CD19 x CD3 TCE, CLN-978, and reinforces the incremental valuation contribution of maintaining both assets in the pipeline, Clear Street adds. The firm has a Buy rating on Cullinan Therapeutics with a price target of $33.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CGEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CGEM
Wall Street analysts forecast CGEM stock price to rise
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.850
Low
24.00
Averages
31.50
High
38.00
Current: 12.850
Low
24.00
Averages
31.50
High
38.00
About CGEM
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Cullinan Therapeutics Options Trading
- Options Selling Risks: Selling puts does not provide investors with CGEM's upside potential, as shares are only owned if the contract is exercised, and without a 32.1% decline, the only gain is a 25.1% annualized return.
- Cost Basis Calculation: If the contract is exercised, the cost basis would be $7.35 per share after deducting the $1.65 premium, highlighting the complexity and risks involved in options trading.
- Historical Volatility Analysis: CGEM's historical volatility is calculated at 73% based on the last 251 trading days, providing crucial insights for investors assessing whether selling the put is worthwhile.
- Market Sentiment Indicator: On Friday, the put volume among S&P 500 components reached 2.92 million contracts, indicating higher demand for puts than the long-term median, reflecting investor concerns about market volatility.
See More
Cullinan Therapeutics Flags 2026 as Key Year for Clinical Data
- 2026 Milestones: Cullinan Therapeutics emphasized at the annual healthcare conference that 2026 will be a pivotal year, with multiple clinical data releases expected for CLN-978 and CLN-049, driving innovation in autoimmune diseases and acute myeloid leukemia.
- Potential of CLN-978: Management described CLN-978 as potentially 'best-in-class,' with plans to release initial clinical data for systemic lupus erythematosus and rheumatoid arthritis in Q2 2026, aiming to mitigate cytokine release syndrome (CRS) risk through step-up dosing.
- FDA Fast Track for CLN-049: CLN-049 demonstrated a 31% composite complete response rate at the ASH conference and received FDA Fast Track designation, with plans to select a recommended Phase II dose and initiate pivotal studies in 2026, indicating strong market potential.
- Funding Support and Strategic Development: The company ended the year with over $430 million in cash, providing a runway into 2029, showcasing Cullinan's ongoing investment capability and competitive position in the biopharmaceutical sector.
See More
Cullinan Therapeutics Reports Wider Q4 Net Loss and R&D Expenses
- Financial Performance: Cullinan Therapeutics reported a net loss of $50.7 million for Q4, widening from $47.6 million the previous year, indicating ongoing financial strain that may affect investor confidence.
- Increased R&D Spending: The full-year R&D expenses reached $187.4 million, a 31% increase from the prior year, reflecting the company's intensified investment in drug development, which may exacerbate losses in the short term.
- Clinical Trial Progress: CLN-978 is undergoing Phase 1 trials for systemic lupus erythematosus and rheumatoid arthritis, with initial data expected in Q2 2026, potentially leading to positive market implications for the company.
- Cash Flow Position: As of December 31, 2025, Cullinan had $439 million in cash and cash equivalents, expected to sustain operations until 2029, indicating a degree of financial stability despite the loss pressures.
See More
Cullinan Therapeutics Q4 Earnings Miss Expectations
- Earnings Report: Cullinan Therapeutics reported a Q4 GAAP EPS of -$0.77, missing the expected -$0.72, indicating challenges in profitability that may affect investor confidence.
- Cash Reserves: As of December 31, 2025, the company held $439 million in cash, cash equivalents, and short- and long-term investments, reflecting strong financial management that supports operations for the coming years.
- Funding Outlook: Cullinan expects its current cash resources to sustain its operating plan into 2029, demonstrating confidence in future growth while providing a safety margin for potential investors.
- Market Potential: Despite the earnings miss, Cullinan's multiple value drivers in oncology may still support future growth, particularly as the company showcases its technological capabilities at the upcoming virtual oncology leadership summit.
See More
Growth Prospects for the EGFR-NSCLC Market Analyzed
- Market Size Forecast: The EGFR-NSCLC market is projected to reach $6 billion by 2024, with the U.S. accounting for approximately 56% of the total market, indicating strong demand for new therapies and significant economic potential in this region.
- Rising Patient Numbers: In 2024, nearly 117,000 new cases of EGFR-NSCLC are expected, and as testing rates increase, more patients with EGFR mutations are identified, driving the demand for targeted therapies and signaling ongoing market expansion.
- Active Drug Development: Several new drugs, including Zipalertinib and Firmonertinib, are in clinical trials and are anticipated to introduce new treatment options, which not only diversify the therapeutic landscape but also have the potential to redefine existing treatment standards and improve patient survival rates.
- Evolving Competitive Landscape: The convergence of TKIs, ADCs, and gene therapies is intensifying competition in the EGFR-NSCLC market, where future winners will depend on efficacy, resistance coverage, and combination therapy potential, driving innovation and growth in the industry.
See More
Major Stocks on the Rise Monday: Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana, and More
U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones dropping over 200 points on Monday, while several companies saw significant gains in their share prices.
Paramount's Acquisition Move: Paramount Skydance Corporation's shares surged nearly 10% after announcing a $30 per share all-cash tender offer to acquire Warner Bros. Discovery, valuing the deal at $108.4 billion.
Biotech Stock Gains: Wave Life Sciences and Structure Therapeutics experienced remarkable increases of 129.1% and 100.5%, respectively, following positive clinical trial results for their obesity treatments.
Other Notable Stock Movements: Companies like Fulcrum Therapeutics and Kymera Therapeutics also saw substantial share price increases due to promising clinical trial data, while Carvana announced its inclusion in the S&P 500, boosting its stock by 11.6%.
See More
Analysis of Cullinan Therapeutics Options Trading
- Options Selling Risks: Selling puts does not provide investors with CGEM's upside potential, as shares are only owned if the contract is exercised, and without a 32.1% decline, the only gain is a 25.1% annualized return.
- Cost Basis Calculation: If the contract is exercised, the cost basis would be $7.35 per share after deducting the $1.65 premium, highlighting the complexity and risks involved in options trading.
- Historical Volatility Analysis: CGEM's historical volatility is calculated at 73% based on the last 251 trading days, providing crucial insights for investors assessing whether selling the put is worthwhile.
- Market Sentiment Indicator: On Friday, the put volume among S&P 500 components reached 2.92 million contracts, indicating higher demand for puts than the long-term median, reflecting investor concerns about market volatility.
See More
Cullinan Therapeutics Flags 2026 as Key Year for Clinical Data
- 2026 Milestones: Cullinan Therapeutics emphasized at the annual healthcare conference that 2026 will be a pivotal year, with multiple clinical data releases expected for CLN-978 and CLN-049, driving innovation in autoimmune diseases and acute myeloid leukemia.
- Potential of CLN-978: Management described CLN-978 as potentially 'best-in-class,' with plans to release initial clinical data for systemic lupus erythematosus and rheumatoid arthritis in Q2 2026, aiming to mitigate cytokine release syndrome (CRS) risk through step-up dosing.
- FDA Fast Track for CLN-049: CLN-049 demonstrated a 31% composite complete response rate at the ASH conference and received FDA Fast Track designation, with plans to select a recommended Phase II dose and initiate pivotal studies in 2026, indicating strong market potential.
- Funding Support and Strategic Development: The company ended the year with over $430 million in cash, providing a runway into 2029, showcasing Cullinan's ongoing investment capability and competitive position in the biopharmaceutical sector.
See More
Cullinan Therapeutics Reports Wider Q4 Net Loss and R&D Expenses
- Financial Performance: Cullinan Therapeutics reported a net loss of $50.7 million for Q4, widening from $47.6 million the previous year, indicating ongoing financial strain that may affect investor confidence.
- Increased R&D Spending: The full-year R&D expenses reached $187.4 million, a 31% increase from the prior year, reflecting the company's intensified investment in drug development, which may exacerbate losses in the short term.
- Clinical Trial Progress: CLN-978 is undergoing Phase 1 trials for systemic lupus erythematosus and rheumatoid arthritis, with initial data expected in Q2 2026, potentially leading to positive market implications for the company.
- Cash Flow Position: As of December 31, 2025, Cullinan had $439 million in cash and cash equivalents, expected to sustain operations until 2029, indicating a degree of financial stability despite the loss pressures.
See More
Cullinan Therapeutics Q4 Earnings Miss Expectations
- Earnings Report: Cullinan Therapeutics reported a Q4 GAAP EPS of -$0.77, missing the expected -$0.72, indicating challenges in profitability that may affect investor confidence.
- Cash Reserves: As of December 31, 2025, the company held $439 million in cash, cash equivalents, and short- and long-term investments, reflecting strong financial management that supports operations for the coming years.
- Funding Outlook: Cullinan expects its current cash resources to sustain its operating plan into 2029, demonstrating confidence in future growth while providing a safety margin for potential investors.
- Market Potential: Despite the earnings miss, Cullinan's multiple value drivers in oncology may still support future growth, particularly as the company showcases its technological capabilities at the upcoming virtual oncology leadership summit.
See More
Growth Prospects for the EGFR-NSCLC Market Analyzed
- Market Size Forecast: The EGFR-NSCLC market is projected to reach $6 billion by 2024, with the U.S. accounting for approximately 56% of the total market, indicating strong demand for new therapies and significant economic potential in this region.
- Rising Patient Numbers: In 2024, nearly 117,000 new cases of EGFR-NSCLC are expected, and as testing rates increase, more patients with EGFR mutations are identified, driving the demand for targeted therapies and signaling ongoing market expansion.
- Active Drug Development: Several new drugs, including Zipalertinib and Firmonertinib, are in clinical trials and are anticipated to introduce new treatment options, which not only diversify the therapeutic landscape but also have the potential to redefine existing treatment standards and improve patient survival rates.
- Evolving Competitive Landscape: The convergence of TKIs, ADCs, and gene therapies is intensifying competition in the EGFR-NSCLC market, where future winners will depend on efficacy, resistance coverage, and combination therapy potential, driving innovation and growth in the industry.
See More
Major Stocks on the Rise Monday: Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana, and More
U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones dropping over 200 points on Monday, while several companies saw significant gains in their share prices.
Paramount's Acquisition Move: Paramount Skydance Corporation's shares surged nearly 10% after announcing a $30 per share all-cash tender offer to acquire Warner Bros. Discovery, valuing the deal at $108.4 billion.
Biotech Stock Gains: Wave Life Sciences and Structure Therapeutics experienced remarkable increases of 129.1% and 100.5%, respectively, following positive clinical trial results for their obesity treatments.
Other Notable Stock Movements: Companies like Fulcrum Therapeutics and Kymera Therapeutics also saw substantial share price increases due to promising clinical trial data, while Carvana announced its inclusion in the S&P 500, boosting its stock by 11.6%.
See More
